Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Novo reports first Ozempic sales drop in greater China region
    Finance

    Novo reports first Ozempic sales drop in greater China region

    Published by Global Banking & Finance Review®

    Posted on February 5, 2026

    2 min read

    Last updated: February 5, 2026

    Novo reports first Ozempic sales drop in greater China region - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:innovationfinancial communitymarket capitalisation

    Quick Summary

    Novo Nordisk's Ozempic sales in China fell for the first time due to competition and price pressures, impacting earnings.

    Table of Contents

    • Ozempic Sales Performance in Greater China
    • Market Competition and New Approvals
    • Impact on Novo Nordisk's Earnings

    Novo Nordisk Sees First Decline in Ozempic Sales in Greater China

    Ozempic Sales Performance in Greater China

    By Andrew Silver

    Market Competition and New Approvals

    SHANGHAI, Feb 5 (Reuters) - Sales of Novo Nordisk's blockbuster diabetes drug Ozempic in the greater China region fell for the first time last year, as it grapples with competition from rivals.

    Impact on Novo Nordisk's Earnings

    The sales drop underscores a bleak outlook from the Danish diabetes drug giant which shocked the market this week by flagging a potential earnings drop, ending years of double-digit gains, due to "unprecedented" price pressures.

    Sales of Ozempic injector pens in mainland China, Taiwan and Hong Kong - Novo's largest market after the U.S. - slipped 7% to about 5.4 billion Danish crowns ($853 million) in 2025.

    Ozempic first won approval from China in 2021 and had until last year only had sales gains there, the company's annual reports show.

    But China has since approved similar drugs including Eli Lilly's Mounjaro, Innovent Biologics' mazdutide and Guangzhou Innogen's efsubaglutide alfa.

    The Innogen and Lilly medicines were added to China's state-run health insurance scheme last month for patients with type 2 diabetes, joining Ozempic.

    Another Chinese drugmaker, Sciwind Biosciences, also said last month that its type 2 diabetes treatment Xianyida has been approved for use in the country.

    "We have a very strong market position with Ozempic, still low penetration, and I would say competition is more entering at this point in time," Novo Chief Financial Officer Karsten Munk Knudsen told Reuters in an interview this week.

    The greater China region accounted for 14% of all 2025 sales in its international operations that exclude the U.S. market, according to a separate investor presentation.

    ($1 = 6.3339 Danish crowns)

    (Reporting by Andrew Silver in Shanghai; Additional reporting by Maggie Fick in London; Editing by Miyoung Kim and Edwina Gibbs)

    Key Takeaways

    • •Novo Nordisk's Ozempic sales in China fell for the first time.
    • •Increased competition from Eli Lilly and Innovent Biologics.
    • •Ozempic sales dropped 7% to 5.4 billion Danish crowns.
    • •China's approval of similar drugs impacts market share.
    • •Potential earnings drop due to price pressures.

    Frequently Asked Questions about Novo reports first Ozempic sales drop in greater China region

    1What is market competition?

    Market competition refers to the rivalry among businesses to attract customers and increase sales. It can influence pricing, product offerings, and overall market dynamics.

    More from Finance

    Explore more articles in the Finance category

    Image for Barclays boosts CEO's pay to more than $20 million
    Barclays boosts CEO's pay to more than $20 million
    Image for JLR to recall 2,278 electric SUVs in US over fire risk warning, NHTSA says
    JLR to recall 2,278 electric SUVs in US over fire risk warning, NHTSA says
    Image for Ryanair and CFM ink multi-billion dollar engine parts deal
    Ryanair and CFM ink multi-billion dollar engine parts deal
    Image for xMoney Expands Domino’s Partnership to Greece, Powering Faster Checkout Experiences
    xMoney Expands Domino’s Partnership to Greece, Powering Faster Checkout Experiences
    Image for Russian attack damages energy facility in Ukraine's southern Odesa region, company says
    Russian attack damages energy facility in Ukraine's southern Odesa region, company says
    Image for Britain secures record amount of solar in renewable power auction
    Britain secures record amount of solar in renewable power auction
    Image for UK's Dunelm flags quarterly sales upswing on winter, spring sales boost
    UK's Dunelm flags quarterly sales upswing on winter, spring sales boost
    Image for Bottler Coca-Cola HBC sees profit rise on strong demand for non-alcoholic drinks
    Bottler Coca-Cola HBC sees profit rise on strong demand for non-alcoholic drinks
    Image for Katie Milligan takes helm at BT's Openreach unit
    Katie Milligan takes helm at BT's Openreach unit
    Image for UK's Bellway sees early signs of housing demand recovery after subdued autumn season
    UK's Bellway sees early signs of housing demand recovery after subdued autumn season
    Image for Monte dei Paschi posts 1.4 billion euro profit after Mediobanca acquisition
    Monte dei Paschi posts 1.4 billion euro profit after Mediobanca acquisition
    Image for France's Macron: FCAS fighter jet programme is not dead
    France's Macron: FCAS fighter jet programme is not dead
    View All Finance Posts
    Previous Finance PostPandora goes platinum-plated to cut reliance on costly silver
    Next Finance PostMaersk flags 2026 earnings hit as Suez return, overcapacity hit freight rates